SSY Group (HKG:2005) obtained registration approval for Safinamide Mesylate to become a bulk drug for the preparations on the market from China's National Medical Products Administration, according to a Tuesday Hong Kong bourse filing.
The drug is mainly used for the treatment of Parkinson's disease in combination with other Parkinson's drugs such as levodopa, the filing said.